BI 905711* is a tetravalent bispecific antibody that cross-links the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) with the tumor cell anchor cadherin 17 (CDH17). CDH17-dependent clustering of TRAILR2 allows BI 905711 to induce selective apoptosis in CDH17-expressing tumor cells.1
Clinical trials: BI 905711 is currently being investigated in patients with advanced gastrointestinal (GI) cancers.2
TRAILR2 is a pro-apoptotic receptor that is widely expressed in normal tissues and in many types of tumors.3,4 Receptor clustering is required for activation of the extrinsic apoptotic pathway.5
CDH17 is a cell-adhesion protein that is broadly expressed on GI tumor cells. It was selected as the anchor target for BI 905711 owing to its limited expression in liver tissue, which may help to avoid clinical hepatotoxicity that can be associated with TRAILR2 agonism.
Mechanism of action
BI 905711 is a tetravalent bispecific antibody that cross-links TRAILR2 with CDH17. The antibody cross-linking induces CDH17-dependent clustering (oligomerization) of TRAILR2, leading to the activation of the apoptotic pathway and killing of CDH17-expressing tumor cells.1
The use of CDH17 as the anchor protein means that BI 905711 is a targeted treatment strategy for CDH17-positive tumors, such as many colorectal cancers (CRC).1
BI 905711 has shown significant inhibition of tumor growth in patient-derived xenograft models of CRC. Tumor regression was sustained for up to approximately 30 days. Decrease in tumor size was accompanied by modulation of apoptosis markers with good correlation between tumor and plasma biomarker modulation.1
BI 905711 is currently being investigated as a monotherapy in patients with advanced GI cancers.
|Trial number||Phase||Treatment||Patient population||Status|
TRAILR2/CDH17 antibody monotherapy
Patients with advanced, unresectable or metastatic gastrointestinal cancers
Explore our latest TRAILR2/CDH17 antibody data
Our latest data on the clinical trial program for the TRAILR2/CDH17 antibody (BI 905711) were presented at the ESMO World Congress on Gastrointestinal Cancer (ESMO WCGC) 2020.
Garcia-Martinez JM, et al. American Association for Cancer Research Annual Meeting 2019; Abstract 2051.
ClinicalTrials.gov. NCT04137289. https://clinicaltrials.gov/ct2/show/NCT04137289 (Accessed: February 2021).
Ashkenazi A, Dixit VM. Science 1998;281:1305–8.
Ashkenazi A, et al. J Clin Invest 1999;104(2):155–62.
Naval J, et al. Cancers (Basel) 2019;11(4):pii: E444.
*This is an investigational compound and has not been approved. Its safety and efficacy have not been established.
© 2021 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: March 2021
Some links in this area will let you leave Boehringer Ingelheim's site and visit external websites. If not indicated otherwise in the imprint of the external website, the linked sites are not under the control of the Boehringer Ingelheim corporation and no entity of the Boehringer Ingelheim group of companies is responsible for the contents of such linked site or any link contained in such linked site, or any changes or updates to such sites. Neither is any entity of the Boehringer Ingelheim group of companies responsible for webcasting or any other form of transmission received from any linked site. These links are provided to you only as a convenience, and the inclusion of any link does not imply endorsement by the Boehringer Ingelheim group of companies of the site. In particular, Boehringer Ingelheim is not in a position to monitor the linked third party websites completely and permanently for violations of the law. Boehringer Ingelheim therefore accepts no responsibility for the accuracy or any other aspect of the information on this website. Boehringer Ingelheim is liable, if at all, only to the extent that it was aware of illegal content and it was technically possible and reasonable to prevent its use. The data protection declaration for this website does not apply to such linked websites.
Do you want to continue ?Continue